Definium Therapeutics Inc. Common Shares (DFTX) Stock Forecast: StockMap's 2-Week Call
DFTX stock forecast: StockMap's model makes no two-week call on Definium Therapeutics Inc. Common Shares after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 2 of 3 two-week windows on DFTX since Oct 2; by chance, a call on the same dates was right 47% of the time.
Definium Therapeutics Inc. Common Shares last closed at $29.48, +1.24% on the session.
Against the IVW growth benchmark the position is +3.57% over the forecast window.
Definium Therapeutics Inc. Common Shares' market cap is $4.04B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -18 (too close to call).
Where DFTX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 67%.
13 daily calls for DFTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Definium Therapeutics Inc. Common Shares in the 12th percentile on return on equity, where 100 is best.
Definium Therapeutics Inc. Common Shares is classified under Health Care / Pharmaceuticals.
StockMap tracks Definium Therapeutics Inc. Common Shares as the 30th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Definium Therapeutics Inc. Common Shares ranks 40th of 153 in the group, against a group median of -0.36.